Blog @ Illumina
Real scientists. Real commentary.

3 Reasons to Attend the NextSeq 500 Demo at Your Institute

Amy Cullinan, Ph.D.
| Feb 05, 2014

NextSeq 500 is coming to youIt’s no secret that researchers are a skeptical bunch; that most rigorous quality is foundational for success in any scientific field. Technology decisions are fueled by data comparisons, depths of information, testimonials, and test drives. After attending one of the first NextSeq 500 demos at the University of California at San Francisco this week, I can assure you that this event is a good investment of your time.

Walk on up and touch the instrument screen, open the door, handle the brand new flow cells, and even take a selfie with the NextSeq. Illumina reps are there to answer questions and guide you around the machine. As the presentation starts, you’ll take in the necessary specs, features, and a few cool tidbits about the system, including the evolution of two-channel  SBS chemistry, and what is recommended for high- vs. mid-output mode. Then, get ready to dive into how NextSeq could transform your research.

Here are my top three “aha !” moments from the presentation:

1.       Fall in love with RNA-Seq all over again. We’ve talked about how NextSeq 500 give you the ideal balance of power and flexibility for transcriptome studies. Now you’ll learn about  BaseSpace Core RNA Apps, the new data analysis pipeline built upon the Tuxedo Suite, but designed to be accessible to an informatics novice. Robust and speedy, with an intuitive, click-and-go user interface and easy-to-interpret, publication-ready outputs, you’ll no longer need to rely on others to move your RNA-Seq project forward.    

2.       Your exome, your way. No matter what your goal is for exome sequencing, NextSeq 500 has you covered, whether you are looking at known variants at 50x, novel variants at 100x or somatic variants at 220x. From detection to discovery, exome coverage is cost effective and scalable, even on challenging samples like low-input or FFPE.

3.       Get inspired by the road ahead. NGS is changing key testing strategies in the clinic, for example, the way reproductive health is assessed with single-test carrier screening for all known diseases, qualifying IVF embryos before implantation, detecting chromosomal anomalies non-invasively during pregnancy to diagnosing newborn disorders. Our understanding of the cancer genome has been transformed revealing unexpected features of tumorigenesis and progression. As these findings move into a translational context, new possibilities for using NGS are being discovered.

This is just a sample of what you’ll get out of these half-day demos. There is a lot more information offered about bioinformatics, cancer and prenatal testing, and  population genetics studies. But don’t take my word for it. Go seek for yourself at one of the February or March events: